Innovative Diagnostic Tool Inbiomotion offers a proprietary single-gene based biomarker test for breast cancer prognosis, highlighting its position as an innovative provider of targeted diagnostic solutions that can complement pathology labs and oncologists seeking precise patient assessments.

Strategic Partnerships Recent collaborations with Palexmedical in Spain and Portugal suggest opportunities to expand distribution and clinical integration, making partnerships with medical device distributors and hospital networks highly promising for increasing market reach.

Clinical Validation The company has demonstrated its test's clinical relevance through long-term follow-up studies published in reputable journals, creating a strong foundation for discussions with healthcare providers and payers focused on evidence-based adoption.

Growth & Investment Supported by institutional investment from Alta Life Sciences and recent sector partnerships, Inbiomotion is positioned for growth initiatives, presenting opportunities for investors or collaborative projects that leverage its innovative biotech platform.

Market Niche Focus With an emphasis on breast cancer biomarker diagnostics and a small, dedicated team, Inbiomotion offers tailored solutions that can be integrated into precision medicine workflows, appealing to companies providing complementary technologies or services in oncology.